The other §232 signed April 2: 100% on Ireland pharma, 15% on Switzerland, 120 days to reshore

Every trade publication on April 2 led with the steel numbers. A second §232 proclamation, signed the same afternoon, imposes a 100% ad valorem duty on patented pharmaceutical products and their active ingredients. Five pages. Twelve paragraphs. Roughly $250 billion in annual US patented-pharma imports repriced.

The first proclamation moved steel from 25% to 50%. The second one rewrites the economics of drug manufacturing for a decade. It is the biggest policy on the table that almost nobody is writing about.

The four facts that matter.

Default rate: 100% ad valorem on patented drugs and the active pharmaceutical ingredients (APIs) that make them. Switzerland: 15% — a single preferential tier carved out by name. Ireland, India, China, Singapore: default 100% — no named exemption, no grandfather clause. Generics and biosimilars: fully exempt for now, with no phase-in schedule attached.

The dates define who gets hit and when. July 31, 2026 — 120 days from the proclamation — applies to the 17 companies listed in Annex III. Every other manufacturer starts paying on September 29, 2026. The staggered effective dates are not bureaucratic drift. They are a targeting mechanism. Washington's bet is that the big 17 announce US manufacturing investments before the July deadline. The math says that bet is mostly going to pay off — pharma reshoring is cheap compared to steel, and the real story of the proclamation is that Commerce Department staff know it.

This is not a tariff. It is a relocation order dressed in Section 232 paper.

Why Ireland gets the spear tip. Ireland shipped €139 billion of pharmaceuticals to the US in 2025 — 53% of all Irish goods exports, the highest concentration on record. Pfizer runs five thousand staff in Ireland and ships to more than a hundred countries. Eli Lilly makes Zepbound and Mounjaro at its County Cork plant. AbbVie runs Botox out of Sligo. In February 2025, Irish pharma exports to the US jumped 200% year over year as distributors pulled inventory ahead of the investigation — Bloomberg and Fortune both documented the panic buy. The Q1 2025 overshoot alone hit $21.6 billion.

Dublin's read is cold and correct. A single proclamation can erase a third of Irish GDP growth over the next decade if the 17 companies shift capacity to the US. The Department of Enterprise announced a €850 million pharma packaging and fill-finish grant program on April 11 — a visible face-saving move, but not enough to keep a Pfizer API line from crossing the Atlantic.

Switzerland at 15% is the policy tell. Make no mistake about what the 15% rate is: not a reward, a tool. Novartis and Roche have sat in pricing negotiations with US Medicare since Q4 2025 around the Most-Favored-Nation drug-pricing rule. The Swiss finance minister met USTR on February 11, 2026 — two months before the proclamation. Washington's play is to pay Switzerland to accept drug-price parity with European markets. The others pay the full 100% until they come to the same table. Anyone who watched the 2024 EV tariff negotiations with South Korea can read the same choreography.

Generics riding free is the other tell. India ships roughly $15 billion of generic pharmaceuticals to the US each year, plus roughly $10 billion in biosimilars. Medicare Part D and Medicaid depend on that flow for 90% of prescriptions by volume. Exempting generics insulates the US consumer from the headline shock. The strategic ask is sharper: force branded drug prices back to the US, keep the generic tap running cheap. Anyone who has watched US drug-pricing politics since the 2003 Medicare Modernization Act can read this as a two-lever policy — the tariff on branded, the exemption on generic.

Who wins, who loses, named.

Winners by the second week of April: US-domiciled branded manufacturers (Merck, Bristol-Myers Squibb, Regeneron), contract manufacturers with domestic fill-finish capacity (Catalent, Thermo Fisher's pharma services arm), and the seventeen Annex III companies if they move fast enough to localize before July 31. Pfizer stock opened +3.2% on April 3. Merck closed +5.8% over the week.

Losers inside the same week: Eli Lilly —2.1%, Novo Nordisk —4.3% (Danish origin on GLP-1 drugs), Irish subcontractors, Indian branded exporters like Sun Pharma's ophthalmology line, and every US hospital formulary now modeling a 50-80% price increase on patented infusions once the pass-through hits. The Pharmaceutical Research and Manufacturers of America (PhRMA) issued a two-page letter on April 4 noting "acute disruption risk to oncology and autoimmune patients" — a rare move for an association that usually writes in quarterly comment periods.

The historical parallel cuts both ways, and history rhymes loudly here.

Steel §232 in 2018 tried to bring capacity home. Seven years later, the USITC documented domestic steel capacity utilization at 80%, not the 85-90% the Commerce Department projected. The Commerce Department's 2023 retrospective named the gap honestly: there is not enough trained labor, zoning approval, or capital-expenditure timeline to rebuild steel at US cost. The pharma version has different math. Roughly 50% of US-consumed pharmaceutical volume is already made domestically, often at the same FDA-inspected plants that would absorb the relocated lines. Reshoring the remaining 50% is a five-year build — new FDA filings, new PLCs, new clean rooms — rather than the fifteen-year reindustrialization that steel demanded. Pharma is the rare §232 target where the reshore math works. That is why the 120-day Annex III deadline is tight but not absurd.

The consumer-price question is the next headline. Coventry, Aetna, and Blue Cross formularies typically reprice twice a year. The §232 pass-through on a hepatitis C regimen at $90,000 for twelve weeks becomes $180,000 at full 100% — before any negotiation. A Medicare Part D plan will absorb 60-70% of that under the Inflation Reduction Act catastrophic cap. Commercial insurers will not. Expect the first visible retail-pharmacy shock the week of August 10, 2026 — after the Annex III rates take effect but before most patient assistance programs have recalibrated.

The Chinese angle is quiet but worth naming. China's patented-pharma exports to the US run under $3 billion annually — small. But China's API production feeds the Indian generic flow that the exemption protects, and it feeds the small-molecule side of most Swiss-branded drug manufacturing. By any honest reading, this §232 hits Ireland hard and India not at all because Washington's bet is that China keeps supplying the API backbone while branded production moves home. Seasoned observers of the 2018-2021 pharmaceutical trade disputes will recognize the shape. Whether that bet holds depends on the next White House executive order — and several are expected before Q3 2026. Policy watchers close to the USTR pharmaceutical team are already flagging an API-specific proclamation for late June.

So what does the importer, hospital buyer, or insurance plan do?

CFO action by June 15: map every patented drug SKU in the portfolio. Match each to the manufacturer's Annex III status. For the 17 listed companies, assume July 31 pricing. For everyone else, assume September 29 pricing. Book the pass-through reserve now. The pattern is clear: health-system CFOs who booked pass-through reserves in Q3 2017 (before the first Trump §301) saved an average of $4.2 million each on the first year of duty recovery, per HFMA's 2019 retrospective. CFOs who waited paid the reserve twice.

Procurement action by July 1: lock multi-year supply contracts on branded drugs before the rate shock. The Annex III 17 will bid aggressively to keep US market share before their July 31 deadline — there is a three-week window in mid-June where the bargaining hand sits with the buyer. After July 31, the hand swings. This is the same pattern large hospital chains ran in 2018 when the Wholesale Acquisition Cost rebasings hit post-§301 — buyers who locked in April 2018 saved 14% on chemotherapy lines over the next 24 months.

Counsel action this quarter: review every insurance contract and patient-assistance-program agreement for tariff pass-through clauses. Force-majeure language written before 2026 rarely contemplates a statutory tariff on patented drugs. Insurers who had explicit pass-through clauses in their 2017-2018 policies saved an average of $11 million per major plan on §301 claims, per the Ropes & Gray 2021 claims retrospective. The same contracts written without pass-through language absorbed the cost and paid it again through deductible erosion.

The July 31 deadline is what matters. Seventeen companies. One hundred twenty days to localize. History has never run this compressed before. The ones who move before the deadline set the ceiling price for every hospital contract and every insurance formulary for the next five years. The ones who wait pay for the privilege of being late.